Bosera Hang Seng SCHK Innovative Drug Select ETF

513060

520690

China Merchants Securities has initiated coverage on Kanion Pharmaceutical, expecting net profits of RMB 1.65 billion, RMB 1.96 billion, and RMB 2.27 billion for the years 2025 to 2027, with annual growth rates of 1.5%, 18.9%, and 15.8%, respectively. The report indicates that Kanion Pharmaceutical has absorbed the impact of centralized procurement and has transformed into a full-chain innovative pharmaceutical company. Although there will be short-term performance fluctuations, the launch of innovative products starting in 2024 is expected to bring a turning point in performance. The company focuses on specialties and operates independently in skin health, ophthalmology, and Southeast Asian markets

AASTOCKS

Guotai CSI Bio-medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

E Fund CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Kanion Pharmaceutical

Minsheng Royal CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai SSE STAR Brand Name Drug ETF

China Universal 800 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

Honz

China Merchants CSI Biotechnology Theme ETF

Yinhua CSI Innovative Drugs Industry ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

"Large Firms" China Merchants Securities initiates coverage on Kanion Pharmaceutical, expects the impact of centralized procurement to be digested

516820

Insilico Medicine and Hygtia Therapeutics, a start-up supported by the Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have recently formed an exclusive partnership to further develop ISM8969 on a global scale. This collaboration involves a shared 50% ownership of worldwide rights between the two companies.

Unusual Whales

VG Health

iShares US Pharma

Hoth Therapeutics

HYGIEIA GROUP

ChinaAMC CSI All Share Health Care Devices ETF

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Huaan Hang Seng Biotech ETF

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Penghua SSE STAR Biology and Medicine ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

SPDR S&P Health

Tianhong CNI BIOMEDICINE ETF

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Ping An CSI Medicine and Medical Device Innovation ETF

FOSUN PHARMA

China Southern Hang Seng Biotech ETF(QDII)

Ark Genomic Revolution ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

VanEck Biotech ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Health Care Select Sector SPDR

ALPS Medical Breakthrough

Insilico Medicine and Hygtia Therapeutics collaborate on ISM8969 for CNS diseases, sharing 50% rights globally.

RemeGen Co. Ltd. has completed its first share buyback, repurchasing 194,144 shares on the Shanghai Stock Exchange for approximately RMB20,004,012. The shares were bought at prices ranging from RMB102.17 to RMB103.78. The buyback was funded through the company's own or self-raised funds and will not impact its business activities, financial condition, or listing status.

Reuters

Yinhua CSI Research Sector 100 ETF

RemeGen

RemeGen Co. Ltd. completes share buyback totaling 194,144 shares for RMB20,004,012

Extrawell Pharmaceutical Holdings Ltd. has announced the resignation of Mr. Fang Lin Hu as Independent Non-Executive Director, effective January 20, 2026. Ms. Yang Xiaorong has been appointed as the new Independent Non-Executive Director and committee member, while Ms. Jin Song will chair the Audit and Remuneration Committees.

EXTRAWELL PHAR

Extrawell Pharmaceutical Appoints Yang Xiaorong as Independent Non-Executive Director

In a report released yesterday, from Zhongtai Securities upgraded RemeGen Co. Ltd. Class H to a Buy, with a price target of HK$114.00.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The word on The Street in general, suggests a Moderate Buy analyst consensus rating for RemeGen Co. Ltd. Class H with a HK$99.54 average price target.

Tip Ranks

REMEGEN

RemeGen Co. Ltd. Class H (9995) was upgraded to a Buy Rating at Zhongtai Securities

600276

01276

Hengrui Pharmaceuticals Gets Nod to Trial Two Tumor Drugs

marketscreener

Hengrui Pharma

HENGRUI PHARMA

Hengrui Pharmaceuticals Gets Nod to Trial Two Tumor Drugs

Ant Group has enhanced its AI health assistant, AQ, on its PC platform by introducing DeepSearch, a feature designed to support evidence-based clinical decision-making. This upgrade is available for free to clinicians and medical students, offering functionalities such as Health Q&A and medical literature searches. This initiative reflects Ant Group's dedication to aiding healthcare professionals in their decision-making processes.

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Hwabao WP CSI Pharmaceuticals ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Ant Group upgrades AI health service AQ's PC platform with DeepSearch for evidence-based clinical decision support, available free to clinicians.

ALPHAMAB-B (9966.HK) has seen a continuous decline after the market closed on January 20, with the overall Hong Kong biotechnology sector lacking excitement. The company has not announced any significant clinical progress or financing recently, and although trading volume slightly increased throughout the day, there was no significant action from major players, as investors' focus has shifted back to sector rotation. There are rumors in the news that the adjustment window for the medical insurance catalog is approaching, and market funds are leaning towards innovative drugs and emerging sectors, while ALPHAMAB has not shown significant movement following the hot trends. The intraday fluctuations have been mild, with no significant gathering of major players, and the buying pressure remains to be validated. On the technical side, the MACD continues to trend downward, and the 5-day moving average is providing short-term resistance, raising doubts about the sustainability of any rebound. Moving forward, attention should be paid to the substantive progress of medical insurance negotiations and the future structural rotation of the sector. If the biotechnology sector experiences another overall pullback or if the company faces unexpected negative news, short-term pressure may significantly increase. The operational suggestion is to continue observing from the right side, closely track marginal policy changes and sector movements, and wait for signals of major capital action to emerge

Technical Forecast

CSOP HEALTHCARE

GX CN BIOTECH-U

Hwabao WP CSI Hong Kong Connect Medical Treatment Thematic ETF

Yinhua CSI HK Equities Medical and Health Integration ETF

GX CN BIOTECH

CAM HSBIOTECH-U

Ping An CSI HK Equities Medical and Health Integration ETF

E Fund CSI HK Equities Medical and Health Integration ETF

Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF

CAM HSBIOTECH

ALPHAMAB-B

Morning Trend | ALPHAMAB is testing the bottom with reduced volume, will the main opportunities in the pharmaceutical sector rotate?

Hong Kong stocks rose 32 points (0.1%) to 26,518, breaking a four-session losing streak, influenced by stronger U.S. futures. The rebound was led by tech and consumer sectors, reflecting gains in mainland markets after the People's Bank of China maintained lending rates. However, investor caution persisted ahead of upcoming inflation data and business confidence readings. Notable early movers included Wuxi Biologics (2.6%), SMIC (2.5%), Zijin Mining (2.2%), and China Hongqiao Group (1.9%).

Trading Economics

ICBCCS CNI HK Equities Technology ETF

Dacheng Hang Seng Technology ETF(QDII)

HSTECH ETF

CHINAHONGQIAO

ISHARESHSI

ZIJIN MINING

WuXi Biologics

WUXI BIO

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

Zijin Mining

HSCEI ETF

Hang Seng Index

Tianhong Hang Seng TECH ETF(QDII)

ChinaAMC Hang Seng Technology ETF(QDII)

SMIC

Hong Kong Equities Edge Up After Recent Declines

Hengrui Pharmaceuticals' Unit Gets Nod to Trial Diabetes Drugs

Hengrui Pharmaceuticals' Unit Gets Nod to Trial Diabetes Drugs

Shanghai Pharmaceuticals' Unit Gets Nod for B023 Cell Injection Trial

SH PHARMA

GF CSI All Share Health Care ETF

Shanghai Pharma

Shanghai Pharmaceuticals' Unit Gets Nod for B023 Cell Injection Trial

China Resources Pharmaceutical Group Ltd. has scheduled its first extraordinary general meeting for February 6, 2026, in Beijing. Shareholders will vote on a new Sales Framework Agreement for 2026-2028 and a special resolution to adopt new Articles of Association, potentially updating the company's governance framework. The current analyst rating for the stock (HK:3320) is a Hold with a price target of HK$5.00. The company operates in the pharmaceutical sector in mainland China, with a market cap of HK$28.52B and a year-to-date price performance of 2.02%.

CHINARES PHARMA

China Resources Pharmaceutical Calls 2026 EGM to Approve Sales Framework and New Articles

Bosera Hang Seng SCHK Innovative Drug Select ETF(520690.SH)

"Large Firms" China Merchants Securities initiates coverage on Kanion Pharmaceutical, expects the impact of centralized procurement to be digested

Insilico Medicine and Hygtia Therapeutics collaborate on ISM8969 for CNS diseases, sharing 50% rights globally.

RemeGen Co. Ltd. completes share buyback totaling 194,144 shares for RMB20,004,012

Extrawell Pharmaceutical Appoints Yang Xiaorong as Independent Non-Executive Director

RemeGen Co. Ltd. Class H (9995) was upgraded to a Buy Rating at Zhongtai Securities